Exelixis, Inc. EXEL
2 trading plans running, 25 Form 144 notices for $40.1M
10-Q, 10-K and Form 144What EXEL's directors and officers said they would sell, before they sold: trading plans the company reports each quarter, and the Form 144 notices sellers file on the day of a planned sale. Most of these sales are routine, such as selling shares from vesting stock awards.
Plans adopted or ended
Trading plans · XBRL, 10-Q and 10-K
From Feb 12, 2024 to Jun 18, 2027. The thin line is today; a filled bar is a plan still running, a paler one has ended or expired. The ten newest plans are drawn; all are in the table.
| Insider | What | Date | Reported in | ||
|---|---|---|---|---|---|
| Mary C. Beckerle Board of Directors |
Adopted 10b5-1 plan | May 8, 2026 | 10-Q Aug 5, 2026 | ||
| Brenda J. Hefti Senior Vice President and General Counsel |
Adopted 10b5-1 plan | Nov 19, 2025 | 10-K Feb 10, 2026 | ||
What the company wroteBrenda J. Hefti, our Senior Vice President and General Counsel, an officer for purposes of Section 16 of the Exchange Act, modified an existing 10b5-1 trading plan that was originally entered on February 26, 2025. Dr. Hefti’s modified trading plan provides for the sale of up to 30,202 shares of our common stock between February 18, 2026 and May 29, 2026. This modified trading plan is intended to satisfy the affirmative defense of Rule 10b5-1(c) under the Exchange Act and Exelixis’ policies regarding transactions in Exelixis securities. | |||||
| Jack L. Wyszomierski member of our Board of Directors |
Adopted 10b5-1 plan | Nov 19, 2025 | 10-K Feb 10, 2026 | ||
What the company wroteJack L. Wyszomierski, a member of our Board of Directors, entered into a pre-arranged stock trading plan on November 19, 2025. Mr. Wyszomierski’s trading plan provides for the sale of up to 114,746 shares of our common stock (including shares obtained from the exercise of vested stock options covered by the trading plan) between February 18, 2026 and November 19, 2026. This trading plan is intended to satisfy the affirmative defense of Rule 10b5-1(c) under the Exchange Act and Exelixis’ policies regarding transactions in Exelixis securities. | |||||
| S. Gail Eckhardt member of our Board of Directors |
Adopted 10b5-1 plan | Nov 11, 2025 | 10-K Feb 10, 2026 | ||
What the company wroteS. Gail Eckhardt, a member of our Board of Directors, entered into a pre-arranged stock trading plan on November 11, 2025. Dr. Eckhardt’s trading plan provides for the sale of up to 13,668 shares of our common stock between February 13, 2026 and June 30, 2026. This trading plan is intended to satisfy the affirmative defense of Rule 10b5-1(c) under the Exchange Act and Exelixis’ policies regarding transactions in Exelixis securities. | |||||
| Amy C. Peterson Executive Vice President, Product Development and Medical Affairs, and Chief Medical Officer |
Adopted 10b5-1 plan | Feb 13, 2025 | 10-Q May 13, 2025 | ||
What the company wroteAmy C. Peterson, our Executive Vice President, Product Development and Medical Affairs, and Chief Medical Officer, an officer for purposes of Section 16 of the Exchange Act, entered into a pre-arranged stock trading plan on February 13, 2025. Ms. Peterson’s trading plan provides for the sale of up to 72,776 shares of our common stock (including shares obtained from the exercise of vested stock options covered by the trading plan) between May 16, 2025 and March 2, 2026. This trading plan is intended to satisfy the affirmative defense of Rule 10b5-1(c) under the Exchange Act and Exelixis’ policies regarding transactions in Exelixis securities. | |||||
| Jack L Wyszomierski Board of Directors |
Adopted 10b5-1 plan | Nov 29, 2024 | 10-K Feb 11, 2025 | ||
| S. Gail Eckhardt Board of Directors |
Adopted 10b5-1 plan | Oct 30, 2024 | 10-K Feb 11, 2025 | ||
| Patrick J. Haley Executive Vice President, Commercial |
Adopted 10b5-1 plan | Aug 19, 2024 | 10-Q Oct 29, 2024 | ||
What the company wrotePatrick J. Haley, our Executive Vice President, Commercial, an officer for purposes of Section 16 of the Exchange Act, entered into a pre-arranged stock trading plan on August 19, 2024. Mr. Haley’s trading plan provides for the sale of up to 72,207 shares of our common stock between November 18, 2024 and August 19, 2025. This trading plan is intended to satisfy the affirmative defense of Rule 10b5-1(c) under the Exchange Act and Exelixis’ policies regarding transactions in Exelixis securities. | |||||
| Jeffrey J. Hessekiel Executive Vice President, General Counsel and Secretary |
Adopted 10b5-1 plan | Feb 28, 2024 | 10-Q Apr 30, 2024 | ||
What the company wroteJeffrey J. Hessekiel, our Executive Vice President, General Counsel and Secretary, an officer for purposes of Section 16 of the Exchange Act, entered into a pre-arranged stock trading plan on February 28, 2024. Mr. Hessekiel’s trading plan provides for the sale of up to 200,000 shares of our common stock (including shares obtained from the exercise of vested stock options covered by the trading plan) between May 29, 2024 and December 31, 2024. This trading plan is intended to satisfy the affirmative defense of Rule 10b5-1(c) under the Exchange Act and Exelixis’ policies regarding transactions in Exelixis securities. | |||||
| Jack L Wyszomierski Board of Directors |
Adopted 10b5-1 plan | Feb 12, 2024 | 10-Q Apr 30, 2024 | ||
What the company wroteJack L Wyszomierski, a member of our Board of Directors, entered into a pre-arranged stock trading plan on February 12, 2024. Mr. Wyszomierski’s trading plan provides for the sale of up to 19,973 shares of our common stock (including shares obtained from the exercise of vested stock options covered by the trading plan) between May 13, 2024 and June 12, 2024. This trading plan is intended to satisfy the affirmative defense of Rule 10b5-1(c) under the Exchange Act and Exelixis’ policies regarding transactions in Exelixis securities. | |||||
| Alan M. Garber Board of Directors |
Adopted 10b5-1 plan | Nov 8, 2023 | 10-K Feb 6, 2024 | ||
| Patrick J. Haley Executive Vice President, Commercial |
Adopted 10b5-1 plan | Aug 7, 2023 | 10-Q Nov 1, 2023 | ||
| Dana T. Aftab Executive Vice President, Discovery and Translational Research, and Chief Scientific Officer |
Adopted 10b5-1 plan | May 25, 2023 | 10-Q Apr 30, 2024 | ||
What the company wroteDana T. Aftab, our Executive Vice President, Discovery and Translational Research, and Chief Scientific Officer, an officer for purposes of Section 16 of the Exchange Act, entered into a pre-arranged stock trading plan on May 25, 2023, which was subsequently modified on February 27, 2024. As modified, Dr. Aftab’s trading plan provides for the sale of up to 194,656 shares of our common stock (including shares obtained from the exercise of vested stock options covered by the trading plan) between May 30, 2024 and September 30, 2025. This trading plan is intended to satisfy the affirmative defense of Rule 10b5-1(c) under the Exchange Act and Exelixis’ policies regarding transactions in Exelixis securities. | |||||
| Dana T. Aftab Executive Vice President, Discovery and Translational Research, and Chief Scientific Officer |
Adopted 10b5-1 plan | May 25, 2023 | 10-Q Aug 1, 2023 | ||
Show the other 6 plans
From the XBRL of the company's 10-Qs and 10-Ks (Regulation S-K Item 408, reported since 2023): 15 filings checked since May 9, 2023.
Notices of planned sales
Form 144 · Form 144 XML, SEC
What the sellers expected to sell on the Form 144 notices filed each month (the value on the notice).
| Filed | Seller | Shares | Value |
|---|---|---|---|
| Aug 10, 2026 | MARY BECKERLE Director |
9,812 | $526K |
| Jun 1, 2026 | Eckhardt Sue Gail Director |
9,812 | $499K |
| Jun 1, 2026 | JACK L WYSZOMIERSKI Director |
3,925 | $198K |
| May 26, 2026 | DANA T AFTAB Officer |
43,451 | $2.2M |
| May 20, 2026 | PATRICK JOSEPH HALEY Officer |
32,110 | $1.6M |
| May 18, 2026 | CHRISTOPHER J SENNER Officer |
34,901 | $1.7M |
| May 18, 2026 | BRENDA JOY HEFTI Officer |
6,625 | $333K |
| May 14, 2026 | BOMBORA RISE FOUNDATION Family foundation of the CEO of EXEL. |
100,000 | $5.1M |
| May 7, 2026 | MARY BECKERLE Director |
7,712 | $374K |
| May 7, 2026 | GEORGE H POSTE Director |
60,000 | $2.7M |
| May 7, 2026 | MARIA C FREIRE Director |
20,634 | $949K |
| Feb 24, 2026 | DANA T AFTAB Officer |
47,918 | $2.1M |
| Feb 19, 2026 | DANA T AFTAB Officer |
29,873 | $1.3M |
| Feb 18, 2026 | JULIE ANNE SMITH Director |
64,117 | $2.8M |
| Feb 18, 2026 | BRENDA JOY HEFTI Officer |
18,669 | $822K |
| Feb 18, 2026 | JACK L WYSZOMIERSKI Director |
99,574 | $4.4M |
| Feb 17, 2026 | JULIE ANNE SMITH Director |
42,422 | $1.9M |
| Feb 17, 2026 | CHRISTOPHER J SENNER Officer |
30,617 | $1.3M |
| Feb 17, 2026 | PATRICK JOSEPH HALEY Officer |
67,814 | $3.0M |
| Feb 13, 2026 | Eckhardt Sue Gail Director |
3,856 | $165K |
| Feb 13, 2026 | CHRISTOPHER J SENNER Officer |
34,278 | $1.5M |
| Feb 13, 2026 | ROBERT L OLIVER Director |
30,250 | $1.3M |
| Feb 12, 2026 | BOMBORA RISE FOUNDATION Family foundation of the CEO of EXEL. |
5,000 | $216K |
| Dec 12, 2025 | Haley Patrick J. Officer, Member of immediate family of any of the foregoing |
62,230 | $2.6M |
| Nov 20, 2025 | PATRICK JOSEPH HALEY Officer |
10,000 | $421K |
Show the other 17 notices
From the Form 144 XML filed with the SEC, since Nov 20, 2025. The value is the seller's estimate on the notice. "Form 4 sales after" matches the seller's Form 4 sales in the 30 days after the notice, by name; Form 4s go back 180 days.
Sources
Regulation S-K Item 408 in the XBRL of each 10-Q and 10-K (since 2023); the Form 144 XML at the SEC.
Also
Insider trades: the Form 4s for the sales these plans led to.
Work with it
Excel workbook · CSV. Google Sheet that stays up to date: paste =IMPORTDATA("https://tickdelta.com/company/EXEL/export.csv") into a cell.